Allopurinol for mania: A randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder

Bipolar Disorders

Volumn 16, Issue 4, 2014, Pages 441-447

  Weiser, Mark ^a,b   Burshtein, Shimon ^a   Gershon, Ari A ^a   Marian, Gabriela ^c,d   Vlad, Nicolae ^d,e   Grecu, Iosif G ^d,f   Tocari, Elena ^d,g   Tiugan, Alexandru ^d,h   Hotineanu, Mihail ^d,i   Davis, John M ^j  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Spitalul Clinic de Psihiatrie Obregia   (Romania)

^d TGD Tangent Data   (Romania)

^e Spitalul de Psihiatrie Botosani ICBratianu ^*  (Romania)

^f Spitalul Clinic Judetean Mures Sectia Clinica Psihiatrie I Gh Marinescu   (Romania)

^g Spitalul Judetean Vrancea Sectia Psihiatrie Focsani Comisia Centrala   (Romania)

^h Sp Clinic de Urgenta Militar Dr Stefan Odoblegea   (Romania)

ⁱ Spitalul Clinic de Psihiatrie Chisinau   (Moldova)

^j UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

Add on; Allopurinol; Mania; Placebo

Indexed keywords

ALLOPURINOL; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; ANTIDEPRESSANT AGENT; ENZYME INHIBITOR;

ADD ON THERAPY; ADULT; ANEMIA; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSTONIA; FEMALE; GENERAL CONDITION IMPROVEMENT; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MULTICENTER STUDY; NAUSEA; NOCTURIA; OUTCOME ASSESSMENT; PAIN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SOMNOLENCE; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; YOUNG MANIA RATING SCALE; ADOLESCENT; AGED; CLINICAL TRIAL; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLOPURINOL; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); YOUNG ADULT;

EID: 84901939857     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12202     Document Type: Article

References (20)

1. Woods SW. The economic burden of bipolar disease. J Clin Psychiatry 2000; 61 (Suppl. 13): 38-41.
2. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006; 11: 227-240.
3. Ferre S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci U S A 1991; 88: 7238-7241.
4. Fuxe K, Marcellino D, Borroto-Escuela DO et al. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 2010; 16: e18-e42.
5. Shah U, Hodgson R. Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease. Curr Opin Drug Discov Devel 2010; 13: 466-480.
6. Lara DR, Dall'Igna OP, Ghisolfi ES, Brunstein MG. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 617-629.
7. Marro PJ, Mishra OP, Delivoria-Papadopoulos M. Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets. Brain Res 2006; 1073-1074: 444-450.
8. Ferre S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology 1997; 133: 107-120.
9. Kafka SH, Corbett R. Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol 1996; 295: 147-154.
10. Nayak GH, Prentice HM, Milton SL. Neuroprotective signaling pathways are modulated by adenosine in the anoxia tolerant turtle. J Cereb Blood Flow Metab 2011; 31: 467-475.
11. Stone TW, Ceruti S, Abbracchio MP. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009; 193: 535-587.
12. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006; 8: 485-489.
13. Machado-Vieira R, Soares JC, Lara DR et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008; 69: 1237-1245.
14. Fan A, Berg A, Bresee C, Glassman LH, Rapaport MH. Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study. Bipolar Disord 2012; 14: 206-210.
15. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). New York, NY: Biometrics Research, New York State Psychiatric Institute, 1997.
16. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
17. Guy W. CGI: clinical global impressions. In: Guy W, Bonato RR eds. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976: 217-222.
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
19. Buchanan RW, Javitt DC, Marder SR et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593-1602.
20. Weiser M, Davidson M, Heresco-Levy U et al. A multicenter, add-on trial of D-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry 2012; 73: e728-e734.